ElevateBio Life Edit: Opening New Frontiers In Genomic Medicine

By Amy Pooler, Senior Vice President, Research and Development of Life Edit

Life Edit, part of ElevateBio, is pioneering a comprehensive platform for in vivo gene editing, offering unmatched flexibility, precision, and speed in therapeutic development. With the industry’s largest gene editing toolbox, which includes nuclease, base, reverse transcriptase, and epigenetic editors, Life Edit enables tailored solutions for a wide range of diseases, including polygenic and monogenic disorders. Their proprietary CRISPR systems and expansive protein catalog, powered by AI-driven discovery engines, allow for rapid identification and optimization of novel editor candidates.

The platform’s integrated capabilities span editor discovery, protein engineering, off-target analysis, and delivery systems such as LNP and AAV, streamlining the path from concept to clinic. Notable applications include LETI-101 for Huntington’s disease and in vivo editing of HAO1 and PCSK9, demonstrating high potency and safety at low doses. Life Edit’s PAM diversity and protein language models further enhance specificity and broaden genomic access.

By combining advanced computational biology with end-to-end manufacturing and development infrastructure, Life Edit offers a one-stop solution for genetic medicine programs, accelerating timelines and reducing risk. For organizations seeking to expand therapeutic horizons, this platform provides a powerful foundation for innovation.